VOR VS MRK Stock Comparison

Performance

VOR
10/100

VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

MRK
100/100

MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.

Technicals

VOR
10/100

VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

MRK
10/100

MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

VOR
10/100

VOR has missed earnings 6 times in the last 20 quarters.

MRK
53/100

MRK has missed earnings 3 times in the last 20 quarters.

Profit

VOR
10/100

Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

MRK
66/100

Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

VOR
43/100

VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

MRK
52/100

MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

VOR

"Analyst Price Targets" not found for VOR

MRK
68/100

21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.

Dividend

VOR

"Dividend" not found for VOR

MRK
100/100

MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Vor Biopharma Inc. Common Stock Summary

Nasdaq / VOR

Healthcare

Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Merck & Co., Inc. Summary

New York Stock Exchange / MRK

Healthcare

Drug Manufacturers - General

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Power up your portfolio